home / stock / bmy / bmy articles

BMY Articles, Bristol-Myers Squibb Company - From 04/05/24

Stock Information
Company Name: Bristol-Myers Squibb Company
Stock Symbol: BMY
Market: NYSE
Website: bms.com
Menu
BMY BMY Quote BMY Short BMY News BMY Articles BMY Message Board
Get BMY Alerts

News, Short Squeeze, Breakout and More Instantly...
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer | Benzinga

Friday, the FDA approved Bristol-Myers Squibb Company (NYSE:BMY) and  2seventy Bio Inc’s (NASDAQ:TSVT) Abecma&n...
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More | Benzinga

Pipeline and regulatory updates continue to be in focus in the biotech sector. While nothing much came out of bigwigs apart from a few, shares of c...

One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details | Benzinga

Thursday, Bristol Myers Squibb & Co (NYSE:BMY) announced an update following the initial analysis of results from the first of two in...

Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease | Benzinga

Tuesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept-csrk), for injection, 45mg, 60mg for adults with p...
Europe Approves Bristol Myers Squibb's CAR-T Therapy For Early Treatment Of Type Of Blood Cancer | Benzinga

Wednesday, the European Commission approved Bristol Myers Squibb & Co’s (NYSE:BMY) Abecma (idecabtagene vicleucel; ide-cel) for...

GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy | Benzinga

Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary ...

AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments | Benzinga

Tuesday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash p...
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer | Benzinga

Friday, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) favoring expanded use of Bristol Myers Squibb & C...

Bristol Myers' Breyanzi Scores Second FDA Approval For Blood Cancers Therapy | Benzinga

The FDA granted accelerated approval on Thursday to Bristol Myers Squibb Co.’s (NYSE:BMY) of Breyanzi (lisocabtagene maraleucel, li...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY | Benzinga

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ("Bris...
Previous 10 Next 10